Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: a Review of the Society of Thoracic Surgeons Database

Overview

Journal Ann Thorac Surg

Publisher Elsevier

Specialties General Surgery
Pulmonary Medicine

Date 2013 Jun 5

PMID 23731608

Citations 32

Authors

Traves D Crabtree

Andrzej S Kosinski

Varun Puri

William Burfeind

Ankit Bharat

G Alexander Patterson

Wayne Hofstetter

Bryan F Meyers

Affiliations

Soon will be listed here.

Abstract

Background: Clinical staging of esophageal cancer has improved with positron-emission tomography/computed tomography and endoscopic ultrasound imaging. Despite such progress, small single-center studies have questioned the reliability of clinical staging of T2 N0 esophageal cancer. This study broadly examines the adequacy of clinical staging of T2 N0 disease using The Society of Thoracic Surgeons database.

Methods: We retrospectively studied 810 clinical stage T2 N0 patients from 2002 to 2011, with 58 excluded because of incomplete pathologic staging data. Clinical stage, pathologic stage, and preoperative characteristics were recorded. Logistic regression analysis was used to identify factors associated with upstaging at the time of surgical intervention.

Results: Among 752 clinical stage T2 N0 patients, 270 (35.9%) received induction therapy before the operation. Of 482 patients who went directly to surgical intervention, 132 (27.4%) were confirmed as pathologic T2 N0, 125 (25.9%) were downstaged (ie, T0-1 N0), and 225 (46.7%) were upstaged at the operation (T3-4 N0 or Tany N1-3). Exclusive tumor upstaging (ie, pathologic T3-4 N0) accounted for 41 patients (18.2%), whereas exclusive nodal upstaging (ie, pathological T1-2 N1-3) accounted for 100 (44.5%). Combined tumor and nodal upstaging (ie, pathological T3-4 N1-3) accounted for 84 patients (37.3%). Among patients who received induction therapy, 103 (38.1%) were upstaged vs 225 (46.7%) without induction therapy (p = 0.026). Comparing the induction therapy group and the primary surgical group, postoperative 30-day mortality (3.7% vs 3.7%, p > 0.99) and morbidity (46.3% vs 45%, p = 0.76) were similar.

Conclusions: Despite advances in staging techniques, clinical staging of T2 N0 esophageal cancer remains unreliable. Recognizing T2 N0 as a threshold for induction therapy in esophageal cancer, many surgeons have opted to treat T2 N0 disease with induction therapy, even though one-quarter of these patients will be pathologic T1 N0. Although this study demonstrated similar perioperative morbidity and mortality with and without induction therapy, further study is needed to examine the effect of upstaging on long-term survival.

Citing Articles

Clinical staging to differentiate T2 and T3 esophageal squamous cell carcinomas-essential details or just noise?.

Groth S J Thorac Dis. 2024; 16(11):7230-7232.

PMID: 39678881 PMC: 11635233. DOI: 10.21037/jtd-24-491.

Radiomics in Oesogastric Cancer: Staging and Prediction of Preoperative Treatment Response: A Narrative Review and the Results of Personal Experience.

Garbarino G, Polici M, Caruso D, Laghi A, Mercantini P, Pilozzi E Cancers (Basel). 2024; 16(15).

PMID: 39123392 PMC: 11311587. DOI: 10.3390/cancers16152664.

Comparison of long-term survival of neoadjuvant therapy plus surgery versus upfront surgery and the role of adjuvant therapy for T1b-2N0-1 esophageal cancer: a population study of the SEER database and Chinese cohort.

Xia L, Shi W, Cai Y, Liao Z, Huang Z, Qiu H Int J Surg. 2024; 111(1):70-79.

PMID: 38920327 PMC: 11745756. DOI: 10.1097/JS9.0000000000001886.

Collaborative multidisciplinary management and expertise of cT2-3 locally advanced operable esophageal squamous cell carcinoma: a report of two cases.

Leng X, Kurita D, Zhu Y, Abe S, Zhang R, Guo X J Thorac Dis. 2023; 15(11):6362-6372.

PMID: 38090303 PMC: 10713291. DOI: 10.21037/jtd-23-1277.

Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study.

Park S, Lee Y, Lee J, Min Y, Kim H, Choi J Cancer Res Treat. 2023; 56(2):567-579.

PMID: 37846467 PMC: 11016664. DOI: 10.4143/crt.2023.897.

References

Graham A, Shrive F, Ghali W, Manns B, Grondin S, Finley R . Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg. 2007; 83(4):1257-64. DOI: 10.1016/j.athoracsur.2006.11.061. View

Rice T, Blackstone E, Adelstein D, Zuccaro Jr G, Vargo J, Goldblum J . Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma. J Thorac Cardiovasc Surg. 2003; 125(5):1091-102. DOI: 10.1067/mtc.2003.404. View

Urschel J, Vasan H, Blewett C . A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2002; 183(3):274-9. DOI: 10.1016/s0002-9610(02)00795-x. View

Rice T, Blackstone E, Rusch V . 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010; 17(7):1721-4. DOI: 10.1245/s10434-010-1024-1. View

Malthaner R, Wong R, Spithoff K . Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol). 2010; 22(4):250-6. DOI: 10.1016/j.clon.2010.02.005. View

Vazquez-Sequeiros E . Nodal staging: number or site of nodes? How to improve accuracy? Is FNA always necessary? Junctional tumors--what's N and what's M?. Endoscopy. 2006; 38 Suppl 1:S4-8. DOI: 10.1055/s-2006-946642. View

Rice T, Mason D, Murthy S, Zuccaro Jr G, Adelstein D, Rybicki L . T2N0M0 esophageal cancer. J Thorac Cardiovasc Surg. 2007; 133(2):317-24. DOI: 10.1016/j.jtcvs.2006.09.023. View

Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy T . A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335(7):462-7. DOI: 10.1056/NEJM199608153350702. View

Tepper J, Krasna M, Niedzwiecki D, Hollis D, Reed C, Goldberg R . Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26(7):1086-92. PMC: 5126644. DOI: 10.1200/JCO.2007.12.9593. View

10.

Li Z, Rice T . Diagnosis and staging of cancer of the esophagus and esophagogastric junction. Surg Clin North Am. 2012; 92(5):1105-26. DOI: 10.1016/j.suc.2012.07.010. View

11.

Kutup A, Link B, Schurr P, Strate T, Kaifi J, Bubenheim M . Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer. Endoscopy. 2007; 39(8):715-9. DOI: 10.1055/s-2007-966655. View

12.

Vazquez-Sequeiros E, Levy M, Clain J, Schwartz D, Harewood G, Salomao D . Routine vs. selective EUS-guided FNA approach for preoperative nodal staging of esophageal carcinoma. Gastrointest Endosc. 2006; 63(2):204-11. DOI: 10.1016/j.gie.2005.08.053. View

13.

DeWitt J, Kesler K, Brooks J, LeBlanc J, McHenry L, McGreevy K . Endoscopic ultrasound for esophageal and gastroesophageal junction cancer: Impact of increased use of primary neoadjuvant therapy on preoperative locoregional staging accuracy. Dis Esophagus. 2005; 18(1):21-7. DOI: 10.1111/j.1442-2050.2005.00444.x. View

14.

Murthy S, Rozas M, Adelstein D, Mason D, Calhoun R, Rybicki L . Induction chemoradiotherapy increases pleural and pericardial complications after esophagectomy for cancer. J Thorac Oncol. 2009; 4(3):395-403. DOI: 10.1097/JTO.0b013e318195a625. View

15.

Crabtree T, Yacoub W, Puri V, Azar R, Zoole J, Patterson G . Endoscopic ultrasound for early stage esophageal adenocarcinoma: implications for staging and survival. Ann Thorac Surg. 2011; 91(5):1509-15. DOI: 10.1016/j.athoracsur.2011.01.063. View

16.

Stiles B, Mirza F, Coppolino A, Port J, Lee P, Paul S . Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease. Ann Thorac Surg. 2011; 92(2):491-6. DOI: 10.1016/j.athoracsur.2011.04.004. View

17.

Gilbert S, Gresham G, Jonker D, Seely A, Maziak D, Shamji F . Impact of patient selection, disease progression, and adverse events on esophageal cancer outcomes after trimodality therapy. Ann Thorac Surg. 2012; 94(5):1659-66. DOI: 10.1016/j.athoracsur.2012.05.044. View

18.

Zhang J, Hooker C, Brock M, Shin J, Lee S, How R . Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. Ann Thorac Surg. 2012; 93(2):429-35. PMC: 4365971. DOI: 10.1016/j.athoracsur.2011.10.061. View

19.

Pech O, Gunter E, Dusemund F, Origer J, Lorenz D, Ell C . Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer. Endoscopy. 2010; 42(6):456-61. DOI: 10.1055/s-0029-1244022. View

20.

Barbour A, Rizk N, Gerdes H, Bains M, Rusch V, Brennan M . Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. J Am Coll Surg. 2007; 205(4):593-601. DOI: 10.1016/j.jamcollsurg.2007.05.010. View